-
公开(公告)号：US08574872B2
公开(公告)日：2013-11-05
申请号：US13486189
申请日：2012-06-01
CPC分类号： C07K14/70503 , A61K9/0019 , A61K9/19 , A61K38/00 , A61K47/26 , C07K14/70532 , Y02A50/465 , Y02A50/481
摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.
摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。
-
公开(公告)号：US20090297518A1
公开(公告)日：2009-12-03
申请号：US12538698
申请日：2009-08-10
申请人： Tasuku Honjo , Nagahiro Minato , Yoshiko Iwai , Shiro Shibayama
发明人： Tasuku Honjo , Nagahiro Minato , Yoshiko Iwai , Shiro Shibayama
IPC分类号： A61K39/395 , A61P31/18 , A61P31/12
CPC分类号： C07K16/2818 , A61K9/0019 , A61K31/7088 , A61K38/1774 , A61K38/212 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/26 , A61K2039/505 , A61K2039/507 , C07K14/70521 , C07K16/18 , C07K16/2803 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C12Q1/025 , G01N33/5011 , G01N33/574 , G01N2500/00 , Y02A50/39 , Y02A50/394 , Y02A50/463 , Y02A50/466
摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于治疗癌症或感染。
-
公开(公告)号：US06406886B1
公开(公告)日：2002-06-18
申请号：US08895810
申请日：1997-07-17
IPC分类号： C12N1512
CPC分类号： C07K16/18 , C07K14/4738
摘要： A cell division mechanism controlling protein which is not expressed in the interphase but is expressed in the nucleus after entering into a cell cycle, in the cell cycle of mammalian cell, and fragments thereof, as well as DNAs coding for said protein or fragments thereof, as well as antibodies against said protein or fragment thereof.
摘要翻译： 控制蛋白质的细胞分裂机制，其在进入细胞周期后，在哺乳动物细胞的细胞周期及其片段以及编码所述蛋白质或其片段的DNA中在间期不表达但在细胞核中表达， 以及针对所述蛋白质或其片段的抗体。
-
公开(公告)号：US5998585A
公开(公告)日：1999-12-07
申请号：US895628
申请日：1997-07-17
CPC分类号： C07K16/18 , C07K14/4738
摘要： A cell division mechanism controlling protein which is not expressed during interphase but is expressed in the nucleus after entering into a cell cycle, in the cell cycle of mammalian cell, and fragments thereof, as well as DNAs coding for this protein or fragments thereof, as well as antibodies against this protein or fragment thereof.
摘要翻译： 控制蛋白质的细胞分裂机制，其在间期期间不表达，但在进入细胞周期后，在哺乳动物细胞的细胞周期及其片段中在细胞核中表达，以及编码该蛋白质或其片段的DNA作为 以及针对该蛋白质或其片段的抗体。
-
公开(公告)号：US20120269859A1
公开(公告)日：2012-10-25
申请号：US13486189
申请日：2012-06-01
CPC分类号： C07K14/70503 , A61K9/0019 , A61K9/19 , A61K38/00 , A61K47/26 , C07K14/70532 , Y02A50/465 , Y02A50/481
摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.
摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。
-
公开(公告)号：US08216996B2
公开(公告)日：2012-07-10
申请号：US12281427
申请日：2007-03-02
IPC分类号： A61K38/00
CPC分类号： C07K14/70503 , A61K9/0019 , A61K9/19 , A61K38/00 , A61K47/26 , C07K14/70532 , Y02A50/465 , Y02A50/481
摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.
摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。
-
公开(公告)号：US08168179B2
公开(公告)日：2012-05-01
申请号：US12538698
申请日：2009-08-10
申请人： Tasuku Honjo , Nagahiro Minato , Yoshiko Iwai , Shiro Shibayama
发明人： Tasuku Honjo , Nagahiro Minato , Yoshiko Iwai , Shiro Shibayama
IPC分类号： A61K39/395
CPC分类号： C07K16/2818 , A61K9/0019 , A61K31/7088 , A61K38/1774 , A61K38/212 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/26 , A61K2039/505 , A61K2039/507 , C07K14/70521 , C07K16/18 , C07K16/2803 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C12Q1/025 , G01N33/5011 , G01N33/574 , G01N2500/00 , Y02A50/39 , Y02A50/394 , Y02A50/463 , Y02A50/466
摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于治疗癌症或感染。
-
公开(公告)号：US20060110383A1
公开(公告)日：2006-05-25
申请号：US10519925
申请日：2003-07-02
申请人： Tasuku Honjo , Nagahiro Minato , Yoshiko Iwai , Shiro Shibayama
发明人： Tasuku Honjo , Nagahiro Minato , Yoshiko Iwai , Shiro Shibayama
IPC分类号： A61K39/395 , A61K38/17 , A61K48/00
CPC分类号： C07K16/2818 , A61K9/0019 , A61K31/7088 , A61K38/1774 , A61K38/212 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/26 , A61K2039/505 , A61K2039/507 , C07K14/70521 , C07K16/18 , C07K16/2803 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C12Q1/025 , G01N33/5011 , G01N33/574 , G01N2500/00 , Y02A50/39 , Y02A50/394 , Y02A50/463 , Y02A50/466
摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that selects the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for cancer or infection treatment.
-
公开(公告)号：US08728474B2
公开(公告)日：2014-05-20
申请号：US12959307
申请日：2010-12-02
申请人： Tasuku Honjo , Nagahiro Minato , Yoshiko Iwai , Shiro Shibayama
发明人： Tasuku Honjo , Nagahiro Minato , Yoshiko Iwai , Shiro Shibayama
IPC分类号： A61K39/395
CPC分类号： C07K16/2818 , A61K9/0019 , A61K31/7088 , A61K38/1774 , A61K38/212 , A61K39/3955 , A61K45/06 , A61K47/02 , A61K47/26 , A61K2039/505 , A61K2039/507 , C07K14/70521 , C07K16/18 , C07K16/2803 , C07K16/2827 , C07K2317/21 , C07K2317/24 , C07K2317/54 , C07K2317/73 , C07K2317/76 , C07K2319/30 , C12Q1/025 , G01N33/5011 , G01N33/574 , G01N2500/00 , Y02A50/39 , Y02A50/394 , Y02A50/463 , Y02A50/466
摘要： Compositions for cancer or infection treatment via immunopotentiation caused by inhibition of immunosuppressive signal induced by PD-1, PD-L1, or PD-L2 and therapies using them, immunopotentiative substrates included as the active ingredient, screening methods of the substrates for cancer or infection treatment, cell lines used for the screening methods, evaluation methods that select the substrates for cancer treatment, and carcinoma cell transplanted mammals used for the evaluation methods. The compositions of the present invention that inhibits the function of PD-1, PD-L1, or PD-L2 are useful for treatment of cancer or infection.
摘要翻译： 通过由PD-1，PD-L1或PD-L2诱导的免疫抑制信号的抑制和使用它们的疗法，包括作为活性成分的免疫增强底物，用于癌症或感染的底物的筛选方法由免疫增强引起的癌症或感染治疗的组合物 治疗，用于筛选方法的细胞系，选择用于癌症治疗的底物的评价方法和用于评价方法的癌细胞移植的哺乳动物。 抑制PD-1，PD-L1或PD-L2的功能的本发明的组合物可用于治疗癌症或感染。
-
公开(公告)号：US20090305950A1
公开(公告)日：2009-12-10
申请号：US12281427
申请日：2007-03-02
CPC分类号： C07K14/70503 , A61K9/0019 , A61K9/19 , A61K38/00 , A61K47/26 , C07K14/70532 , Y02A50/465 , Y02A50/481
摘要： As a substance which pharmacologically regulates the function of a cell surface functional molecule, a substance which has specificity and an activity or efficacy equal or superior to an antibody and does not require an advanced production technique and facility for application thereof to a pharmaceutical product has been demanded. The invention relates to a multimer of an extracellular domain of a cell surface functional molecule, particularly a tetramer of an extracellular domain of PD-1 or PD-L1. Further, the invention relates to an application of such a tetramer as a preventive and/or therapeutic agent for cancer, cancer metastasis, immunodeficiency, an infectious disease or the like and an application of PD-1 or PD-L1 as a testing or diagnostic agent or a research agent for such a disease.
摘要翻译： 作为药理学上调节细胞表面功能分子的功能的物质，具有特异性，活性或功效等同于或优于抗体且不需要先进的生产技术的物质及其应用于药物的设备已经被 要求 本发明涉及细胞表面功能分子的细胞外结构域的多聚体，特别是PD-1或PD-L1细胞外结构域的四聚体。 此外，本发明涉及这样的四聚体作为癌症，癌症转移，免疫缺陷，感染性疾病等的预防和/或治疗剂的应用，以及应用PD-1或PD-L1作为检测或诊断 代理人或这种疾病的研究代理人。
-
-
-
-
-
-
-
-
-
搜索结果
13 条记录 (耗时 0.023 秒)